Other

Kemphys Ltd.

Research Foundation Itsuu Laboratory

Shionogi Company Limited

Koichi Shudo

Meiji Seika Kaisha, Ltd.

Hoechst Japan Limited

Takeda Chemical Industries, Inc.

Institute of Medicinal Molecular Design, Inc.

Taiho Pharmaceutical Company Limited

Tsumura Co., Ltd.

Nanoegg Research Laboratories, Inc.

Tokyo Metropolitan Institute for Neurosciences

Shionogi Pharmaceutical Co., Ltd.

Research Founation Itsuu Laboratory

Yasuo Sato

Katsuyoshi Iwamatsu

Fukio Konno

Hiroyuki Kagechika

Kazuko Kobayashi

Megumi Yamada

Yo Isogai

Toshihiko Okamoto

Soshiro Takahashi

Tsutomu Inoue

Kazuyuki Kitamura

Mizuho Inazu

Tatsuo Sugioka

Hideaki Muratake

Miwako Ishido

Hideyuki Tanaka

Hideyuki Suzuki

Terumi Nakajima

Iwao Utsunomiya

Tetsuro Matsuishi

Masayuki Noguchi

Giichi Goto

Kiyoshi Sugiyama

Shoji Hizatate

Ai Ito

Hiroshi Fukasawa

Yohei Amano

Naoko Katsumura

Seiji Shibahara

Tsutomu Iwaki

Tetsuji Asao

Akiko Itai

Yuji Yamada

Tetsuo Shiba

Akihiko Sato

Tamio Fujiwara

Makoto Asashima

Konstanty Wierzba

Shigeharu Inoye

Nobufumi Kawai

Tatsuro Yasukata

Koji Murakami

Masaaki Izumi

Tatsuo Hamazaki

Seishiro Fujii

Mitsuko Takenaga

Yasuyuki Endo

Kazuko Amano

Jiro Shibata

Kohichi Kawahara

Nobuko Fujimaki

Tamaki Jikyo

Masashi Akaike

Michita Suenobu

Madoka Nakagomi

A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.

Medicament for therapeutic treatment of neuropathic disease

A medicament for therapeutic and/or preventive treatment of Alzheimer's disease, which comprises a combination of a retinoic acid receptor (RAR) agonist such as Am80 and a retinoid X receptor (RXR) agonist such as HX630.

Medicament for treatment of Alzheimer's disease

A compound represented by the formula (I) [at least one of R, R, and Rrepresents a cyclic alkyl group, the remaining represents a linear or branched alkyl group; n represents 0 or 1; Rrepresents an amino group or &#x2014;(CX)&#x2014;COOH (m represents 0 to 3, and X represents hydrogen atom); and Rrepresents &#x2014;(CY)&#x2014;COOR(p represents 0 to 3, Y represents hydrogen atom, and Rrepresents hydrogen atom or an alkyl group)], or a salt thereof. 

Silicon-containing carboxylic acid derivative

A compound represented by the formula (I) [Rto Rrepresent an alkyl group, an alkenyl group, and the like; n represents 0 or 1; Rrepresents an amino group or &#x2014;(CX)&#x2014;COOH (m represents 0 to 3, and X represents hydrogen atom); Rrepresents &#x2014;(CY)&#x2014;COOR(p represents an 0 to 3, Y represents hydrogen atom, and Rrepresents hydrogen atom or an alkyl group)], or a salt thereof. 

The invention provides a novel oxazolidinone derivative represented by the formula (I): wherein

Compound having heterocyclic ring

A compound represented by the following general formula (I): [wherein Rand Rrepresent an alkyl group, X represents &#x2014;S&#x2014;, &#x2014;O&#x2014; or &#x2014;NH&#x2014;, Y represents C or N, Rrepresents hydrogen atom or a Calkyl group, Z represents &#x2014;CO&#x2014;N(R)&#x2014; (Rrepresents hydrogen atom or a Calkyl group) or &#x2014;C(R)&#x2550;C(R)&#x2014;CO&#x2014;NH&#x2014; (Rand Rrepresent hydrogen atom or a Calkyl group), Ar represents an aryldiyl group or a heteroaryldiyl group, and Rrepresents &#x2014;COOH, &#x2014;OCH&#x2014;COOH, &#x2014;CH&#x2014;COOH, or &#x2014;CH&#x2014;CH&#x2014;COOH], which has a retinoid action and is useful as an active ingredient of a medicament.

5-membered heterocyclic compound

A compound represented by the following general formula (I) (Rand Rrepresent hydrogen atom, an alkyl group, a halogen atom, etc.; Rand Rrepresent hydrogen atom, an alkyl group, an alkoxy group, or an alkenyl group; Rrepresents hydrogen atom, an alkyl group, or nitro group, and Rrepresents hydrogen atom or an alkyl group), which acts on the transcription process of genes. 

Aromatic amide derivative

A compound represented by the following general formula (I): [Rto Rrepresent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents &#x2014;NH&#x2014;CO&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, &#x2014;N(COR)&#x2014;CO&#x2014;, &#x2014;CO&#x2014;N(COR)&#x2014; (Rand Rrepresent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents &#x2014;Y&#x2014;CH(R)&#x2014;COOH, &#x2014;CHO, &#x2014;CH&#x2550;CH&#x2014;COOH, or &#x2014;COOR(Y represents a single bond, &#x2014;CH&#x2014;, &#x2014;CH(OH)&#x2014;, &#x2014;CO&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, or &#x2014;CO&#x2014;NH&#x2014;CH&#x2014;CO&#x2014;NH&#x2014;, Rrepresents hydrogen atom or a lower alkyl group, and Rrepresents hydrogen atom, &#x2014;CH(R)&#x2014;COOH(Rrepresents hydrogen atom, a lower alkyl group, or hydroxy group), &#x2014;[CHCH&#x2014;O]&#x2014;CH&#x2014;CH&#x2014;OH, &#x2014;CH&#x2014;O&#x2014;[CHCH&#x2014;O]&#x2014;CH&#x2014;OH, or &#x2014;[CH(CH)&#x2014;CO&#x2014;O]&#x2014;CH(CH)&#x2014;COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.

Retinoid prodrug compound

The present invention provides a novel oxazolidinone derivative of the formula (I): wherein Rings A and B are defined as in the specification; Xis a single bond, or a heteroatom-containing group selected from the group consisting of &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;NR&#x2014;, &#x2014;CO&#x2014;, &#x2014;CS&#x2014;, &#x2014;CONR&#x2014;, &#x2014;NRCO&#x2014;, &#x2014;SONR&#x2014;, and NRSO&#x2014;, wherein R, R, R, R, and Rare independently hydrogen or lower alkyl, or lower alkylene or lower alkenylene each optionally interrupted by said heteroatom containing group; and Ris hydrogen, or an organic residue which is able to bind to the 5-position of the oxazolidinone ring in oxazolidinone antimicrobial agents, pharmaceutically acceptable salts and solvates thereof which are useful as an antibacterial agent.

Oxazolidinone derivative having 7-membered hetero ring

A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.

Memory fixation accelerator

A compound represented by the following general formula (I): [wherein Rrepresents hydrogen atom or a Calkyl group, A and B represent &#x2014;(CH)&#x2014;, &#x2014;(CH)&#x2014;or &#x2014;(CH)&#x2014;, X represents &#x2014;N(R)&#x2014;CO&#x2014;(Rrepresents hydrogen atom or a Calkyl group), &#x2014;CO&#x2014;N(R)&#x2014;(Rrepresents hydrogen atom or a Calkyl group), &#x2014;C(R)&#x2550;C(R)&#x2014;(Rand Rrepresent hydrogen atom or a Calkyl group), or &#x2014;N(R)&#x2014;SO&#x2014;(Rrepresents hydrogen atom or a Calkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has a retinoid action and is useful as an active ingredient of a medicament.

Tricyclic amide compound

Memory consolidation promoting agent and method of use

Method for therapeutic treatment of inflammatory bowel disease, including Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a retinoid as an active ingredient to treat the inflammatory bowel disease, the retinoid being selected from the group consisting of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid, 4-[(3,5-bis-trimethylsilylphenyl)carboxamido]benzoic acid, 4-[2,3-(2,5-dimethyl-2,5-hexano)dibenzo[b,f][1,4]thiazepin-11-yl]benzoic acid, and 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid.

Method for treatment of inflammatory bowel disease

Growing community of inventors

Tokyo, Japan

Koichi Shudo